NCT04422613View on ClinicalTrials.gov

Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

October 29, 2021

Conditions
Pneumonia, Viral
Interventions
DIAGNOSTIC_TEST

pulmonary anomalies 4 months after documented COVID-19 pneumonia

Characterization of pulmonary damage with a complete pulmonary assessment 4 months after COVID-19 pneumonia,

Trial Locations (1)

31000

University Hospital of Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT04422613 - Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter